(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
4 September 2008 (04.09.2008)

PCT

(10) International Publication Number
WO 2008/106159 A1

(51) International Patent Classification:
C07D 451/02 (2006.01) *A61K 31/46* (2006.01)

(21) International Application Number:
PCT/US2008/002583

(22) International Filing Date:
27 February 2008 (27.02.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/904,090 28 February 2007 (28.02.2007) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 60/904,090 (CIP)
Filed on 28 February 2007 (28.02.2007)

(71) Applicant *(for all designated States except US)*: **THERAVANCE, INC.** [US/US]; 901 Gateway Boulevard, South San Francisco, California 94080 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **DALZIEL, Sean** [AU/US]; 201 Harrison Street #921, San Francisco, California 94105 (US). **PREZA, Leticia M.** [US/US]; 69 Nordhoff Street, San Francisco, California 94131 (US). **RAPTA, Miroslav** [SK/US]; 411 E. Duane Avenue, Sunnyvale, California 94085 (US). **COLSON, Pierre-Jean** [FR/US]; 301 Bryant Street #403, San Francisco, California 94107 (US).

(74) Agents: **HAGENAH, Jeffrey, A.** et al.; Theravance, Inc., 901 Gateway Boulevard, South San Francisco, California 94080 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US (patent), UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

WO 2008/106159 A1

(54) Title: CRYSTALLINE FORMS OF AN 8-AZABICYCLO[3.2.1]OCTANE COMPOUND

(57) Abstract: The invention provides a crystalline sulfate salt of 3-endo-(8-{2-[cyclohexylmethyl-((S)-2,3-dihydroxy-propionyl)amino]ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)benzamide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline salt forms.